Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01313312 · ClinicalTrials.gov registry record · Phase 3

Dysport® Adult Upper Limb Spasticity Extension Study

A Phase 3 study, sponsored by Ipsen.

Completed
Registry status
Phase 3
Development phase
258
Enrollment target

NCT01313312: Completed Phase 3 study, sponsored by Ipsen.

NCT01313312 is a Phase 3 study that has completed, run by Ipsen. The registered enrollment target is 258 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (67% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01313312, a Phase 3 study, has completed, sponsored by Ipsen.

COMPLETED
Registry status
Phase 3
Development phase
258 participants
Enrollment target

Study Summary

The purpose of this research study is to assess the long term safety of Dysport® in hemiparetic subjects with upper limb spasticity due to stroke or traumatic brain injury over repeated treatment cycles.

Primary Outcome

A TEAE was reported as emergent if it arose (i.e. started or worsened in severity) in the treatment phase after the subject received study medication. Adverse events of special interest (AESIs) were identified as those assessed as being due to remote spread of effect of Dysport®, or any adverse event (AE) that was assessed as a hypersensitivity reaction. TEAEs, AESIs, severe TEAEs, serious adverse events (SAEs), treatment related TEAEs, TEAEs leading to withdrawal and fatal SAEs are summarised b

Interventions

  • BIOLOGICAL Botulinum toxin type A

Trial Details

FieldValue
Enrollment Target 258 participants
Start Date 2011-11
Est. Completion 2014-12
Phase Phase 3
Ipsen

85 total trials

What the finished NCT01313312 record still lists

NCT01313312 is an interventional study that assigns participants to a tested intervention. The registered 258 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (67% lower).

The record links to 0 conditions, and to 1 intervention - of which Botulinum toxin type A is the first listed.

NCT01313312 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01313312 about?

NCT01313312 is a clinical study titled "Dysport® Adult Upper Limb Spasticity Extension Study". The purpose of this research study is to assess the long term safety of Dysport® in hemiparetic subjects with upper limb spasticity due to stroke or traumatic brain injury over repeated treatment cycles.

What is the current status of trial NCT01313312?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 258 participants. The study started on 2011-11. Estimated completion is 2014-12.

What interventions are being tested in trial NCT01313312?

The interventions under investigation include: Botulinum toxin type A (BIOLOGICAL).

Who is sponsoring clinical trial NCT01313312?

This trial is sponsored by Ipsen, which has 85 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01313312's enrollment target sits among peer trials

258 1235th of 2000 higher than 763 of 2,000 other Phase 3 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03785288 · 258 participants · Phase 3

    Vaginal Cuff Brachytherapy Fractionation Study

  • NCT04643002 · 258 participants · Phase 1

    Isatuximab in Combination With Novel Agents in RRMM - Master Protocol

  • NCT04924322 · 258 participants · Phase 2

    Catheter-Related Early Thromboprophylaxis With Enoxaparin Studies

  • NCT05043012 · 258 participants · NA

    Diagnostic Performance Of Non-Endorectal Coil Multiparametric Magnetic Resonance Imaging Of Prostate With Flexible AIR Coil (DoNEMAC Study)

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01313312, the US trial registry maintained by the National Library of Medicine. NCT01313312 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.